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Abstract
Adipose	tissue	inflammation	and	dysfunction	are	associated	with	obesity‐related	in‐
sulin	 resistance	 and	 diabetes,	 but	 mechanisms	 underlying	 this	 relationship	 are	
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1  | INTRODUC TION
The	prevalence	of	type	2	diabetes	has	quadrupled	since	1980	(World	
Health	Organization,	2016).	 It	 is	associated	with	multi‐organ	com‐
plications,	 including	cardiovascular	and	renal	disease.	Obesity	and,	
more	specifically,	dysfunctional	adipose	tissue	are	strongly	associ‐
ated	with	whole‐body	insulin	resistance	and	type	2	diabetes	mellitus	
(Kahn	&	Flier,	2000;	Palmer	et	al.,	2015).	Senescent	cells	accumulate	
in	adipose	tissue	of	obese	and	diabetic	humans	and	mice	(Minamino	
et	al.,	2009;	Schafer	et	al.,	2016;	Tchkonia	et	al.,	2010),	but	it	is	un‐
clear whether they are merely associated with diabetes or if their 
presence is a causal driver.
Cellular	senescence	is	a	cell	fate	that	entails	proliferative	arrest	
and	acquisition	of	a	pro‐inflammatory	senescence‐associated	secre‐
tory	phenotype	(SASP;	Coppe	et	al.,	2008).	Although	senescent	cells	
exist	 in	relatively	small	numbers	in	any	particular	tissue,	they	have	
been associated with multiple diseases of aging and are emerging as 
useful	therapeutic	targets	for	age‐related	diseases,	including	cardio‐
vascular	disease,	pulmonary	fibrosis,	neurodegeneration,	and	osteo‐
porosis	(Farr	et	al.,	2017;	Musi	et	al.,	2018;	Roos	et	al.,	2016;	Schafer	
et	 al.,	 2017).	A	number	of	 stimuli,	 including	potentially	oncogenic,	
inflammatory,	damage‐related,	and	metabolic	 stimuli,	 can	 trigger	a	
senescence	response	(Munoz‐Espin	&	Serrano,	2014).	Components	
of	the	SASP	secreted	by	adipose‐derived	senescent	cells	have	been	
postulated	 to	 confer	 insulin	 resistance	upon	metabolic	 tissues,	 in‐
hibit	 adipogenesis,	 and	 attract	 immune	 cells	 that	 can	 exacerbate	
insulin	 resistance	 (Xu,	 Palmer	 et	 al.,	 2015).	 Here,	 we	 determined	
whether removing senescent cells in the context of obesity improves 
metabolic phenotypes.
Recently,	drugs	that	preferentially	decrease	senescent	cell	bur‐
den,	 termed	 senolytics,	 have	 been	 identified	 (Kirkland,	 Tchkonia,	
Zhu,	Niedernhofer,	&	Robbins,	2017).	We	discovered	the	first	seno‐
lytics based on our observation that senescent cells rely on several 
survival	 pathways,	 including	 those	 regulated	 by	 PI3K/AKT‐,	 p53/
p21/serpine‐,	 HIF‐1α‐,	 and	 BCL‐2/BCL‐XL‐family	 components,	 to	
confer	resistance	to	their	pro‐apoptotic	SASP	and	 intracellular	cell	
damage	signals	(Zhu	et	al.,	2016,2015).	Knowing	this,	we	identified	
dasatinib	 (D)	and	quercetin	 (Q)	as	orally	bioactive	drugs	 that	 tran‐
siently target these survival pathways to induce apoptosis prefer‐
entially	 in	senescent	cells	 (Zhu	et	al.,	2015).	Subsequently,	we	and	
others	found	that	navitoclax,	(ABT263,	which	targets	Bcl‐xL,	Bcl‐2,	
and	Bcl‐w	but	not	Mcl‐1),	is	also	senolytic	(Chang	et	al.,	2016;	Zhu	et	
al.,	2016).	We	showed	that	D	and	Q,	alone	and	in	combination,	cause	
apoptosis	in	senescent	cells	without	significant	effects	in	quiescent	
or	proliferating	cells	(Xu	et	al.,	2018;	Zhu	et	al.,	2015).	Senolytics	do	
not prevent the generation of senescent cells and they are effective 
when	administered	intermittently,	which	could	help	to	mitigate	any	
potential	negative	effects	of	senescent	cell	removal,	such	as	delayed	
wound	healing	(Demaria	et	al.,	2017;	Zhu	et	al.,	2015).
We	employed	the	combination	of	D	plus	Q	(D	+	Q)	in	our	studies	
for	 the	following	reasons.	 (a)	 In	our	hands,	no	senolytic	 investigated	
thus	 far	 targets	 all	 types	 of	 senescent	 cells	 (Kirkland	 &	 Tchkonia,	
2017).	 For	 example,	 unlike	 navitoclax	 (ABT263),	 fisetin,	 A1331852,	
A1155463	(Zhu	et	al.,	2017,2016,2015),	or	Q	on	its	own,	D	selectively	
targets	senescent	adipose	progenitors	(Zhu	et	al.,	2015),	a	key	cell	type	
for	adipose	tissue	and	metabolic	function	(Tchkonia	et	al.,	2013).	(b)	On	
the	other	hand,	Q,	unlike	D,	is	effective	against	senescent	endothelial	
cells	(Zhu	et	al.,	2015),	a	cell	type	implicated	in	vascular	complications	
of	diabetes	(Caballero,	2003).	(c)	D	+	Q	is	effective	in	alleviating	mul‐
tiple	 age‐	 and	 senescence‐associated	disorders,	 including	many	 that	
are	frequent	complications	or	comorbidities	of	diabetes	in	preclinical	
animal	models;	 these	comorbidities	 include	arteriosclerosis,	 vascular	
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unclear.	Although	senescent	cells	accumulate	in	adipose	tissue	of	obese	humans	and	
rodents,	a	direct	pathogenic	role	for	these	cells	 in	the	development	of	diabetes	re‐
mains	 to	 be	demonstrated.	Here,	we	 show	 that	 reducing	 senescent	 cell	 burden	 in	
obese	mice,	either	by	activating	drug‐inducible	“suicide”	genes	driven	by	the	p16Ink4a 
promoter	or	by	treatment	with	senolytic	agents,	alleviates	metabolic	and	adipose	tis‐
sue	dysfunction.	These	senolytic	interventions	improved	glucose	tolerance,	enhanced	
insulin	sensitivity,	lowered	circulating	inflammatory	mediators,	and	promoted	adipo‐
genesis	in	obese	mice.	Elimination	of	senescent	cells	also	prevented	the	migration	of	
transplanted	monocytes	into	intra‐abdominal	adipose	tissue	and	reduced	the	number	
of	macrophages	in	this	tissue.	In	addition,	microalbuminuria,	renal	podocyte	function,	
and cardiac diastolic function improved with senolytic therapy. Our results implicate 
cellular	senescence	as	a	causal	factor	in	obesity‐related	inflammation	and	metabolic	
derangements and show that emerging senolytic agents hold promise for treating 
obesity‐related	metabolic	dysfunction	and	its	complications.
K E Y W O R D S
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hyporeactivity,	osteoporosis,	 hepatic	 steatosis,	 physical	dysfunction,	
neurodegeneration,	 and	 neuropsychiatric	 dysfunction	 (Farr	 et	 al.,	
2017;	 Kirkland	 &	 Tchkonia,	 2017;	 Kirkland	 et	 al.,	 2017;	Musi	 et	 al.,	
2018;	Ogrodnik	et	al.,	2017,2019;	Roos	et	al.,	2016;	Xu	et	al.,	2018).	
(d)	Navitoclax	and	other	BCL‐2	family	member	inhibitors	can	be	toxic,	
for	example,	causing	severe	thrombocytopenia,	which	can	occur	even	
with	 intermittent	 dosing	 (Wilson	 et	 al.,	 2010).	 Navitoclax	 can	 also	
cause	neutropenia,	complicating	interpretation	of	whether	its	effects	
are	due	to	senolytic	activity	or	immune	system	suppression.	For	these	
reasons,	we	elected	to	focus	on	D	+	Q.
Here,	we	characterize	the	effects	of	eliminating	senescent	cells	on	
obesity‐induced	derangements	in	adipose	tissue	function	and	glucose	
homeostasis.	To	do	this,	we	used	both	transgenic	mouse	models	and	
treatment	with	 the	 senolytics,	D	+	Q.	Our	 findings	 support	 the	 idea	
that senescent cells could be a novel therapeutic target for treating 
obesity‐induced	metabolic	dysfunction.
2  | RESULTS
2.1 | Senescent cells accumulate in visceral fat in 
obesity
We	 used	 two	 transgenic	 mouse	 models	 from	 which	 senescent	
cells	can	be	selectively	cleared:	(a)	p16‐3MR	mice,	in	which	a	long	
p16Ink4a‐promoter	 sequence	 drives	 expression	 of	 a	 trimodal	 re‐
porter‐killer	 fusion	 protein	 (3MR),	 allowing	 senescent	 cell	 killing	
F I G U R E  1  Removal	of	obesity‐induced	senescent	cells	from	adipose	tissue.	(a,	b)	Renilla	luciferase	activity	in	DIO	p16‐3MR	mice	(a,	
representative	image),	quantified	in	b	(n	=	6–9	per	group).	(c)	Renilla	luciferase	activity	localization	in	DIO	p16‐3MR	dissected	tissues.	(d,	
e)	Senescence‐associated	beta‐galactosidase	(SA‐β‐gal)	activity	as	whole	tissue	activity	(d;	representative	image)	and	%	positive	cells	of	
total	DAPI+	cells	in	p16‐3MR	VAT	(e;	chow	n	=	3,	DIO	n	=	7–9	per	group).	(f)	Expression	of	p16‐3MR	transgene	(eGFP)	components	(Renilla 
luciferase	and	mRFP)	and	p16Ink4a	(chow	n	=	3,	DIO	n	=	11	per	group)	in	p16‐3MR	VAT.	(g,	h)	Senescence‐associated	beta‐galactosidase	
(SA‐β‐gal)	activity	as	whole	tissue	activity	(g;	representative	image)	and	%	positive	cells	of	total	DAPI+	cells	in	p16‐3MR	VAT	(h;	n	=	3–4	
per	group).	(i)	p16Ink4a	mRNA	levels	(c;	chow	n	=	8,	DIO	n	=	19–21	per	group)	in	VAT	of	D	+	Q‐treated	DIO	mice.	(j)	Percent	of	VAT	stromal	
vascular	fraction	(SVF)	cells	highly	expressing	FLAG	(a	component	of	the	p16Ink4a	promoter‐driven	ATTAC	fusion	protein),	CENP‐B,	and	
p21Cip1	after	a	single	course	of	D	+	Q	(o,	n	=	6	per	group)	in	DIO	INK‐ATTAC	mice.	Means	±	SEM	are	shown.	Box	and	whisker	plot	show	
minimum,	mean,	maximum,	25th	and	75th	percentiles.	*p	<	0.05,	**p	<	0.005,	***p	<	0.0005;	one‐way	ANOVA	with	Bonferroni	correction	or	
two‐tailed	Student's	t test when comparing two groups
 
Chow DIO
Veh GCV
DIO
luminescence
600
550
500
450
400
350
Counts
KidneysSubscapular fat
Perirenal fat
Mesenteric fat
Liver
Inguinal fat
Perigonadal fatPancreas Spleen
min  = 323
max = 609 
Muscle
(a)
Chow
DIO 
Vehicle
DIO 
D+Q
Chow
DIO 
Vehicle
DIO 
Ganciclovir
(b) (c)
(d) (e)
(g) (h) (i)
(f)
(j)
4 of 15  |     PALMER Et AL.
by	 ganciclovir	 (GCV)	 and	 identification	 by	 whole‐body	 lumines‐
cence	 (Demaria	 et	 al.,	 2014)	 and	 (b)	 INK‐ATTAC	 mice,	 in	 which	
a truncated p16Ink4a‐promoter	 sequence	 drives	 expression	 of	 a	
vFKBP‐caspase‐8‐FLAG	 fusion	 protein	 that	 can	 be	 activated	 by	
AP20187,	 a	 vFKBP	 dimerizer,	 to	 cause	 senescent	 cell	 apoptosis	
(Baker	et	al.,	2011).	Cells	that	highly	express	p16Ink4a are targeted 
in	the	INK‐ATTAC	and	p16‐3MR	models.	However,	not	all	cells	with	
high	 p16Ink4a	 expression	 are	 senescent,	 and	 not	 every	 senescent	
cell	 highly	 expresses	 p16Ink4a	 (Hall	 et	 al.,	 2017;	 Okuma,	 Hanyu,	
Watanabe,	&	Hara,	2017),	limiting	the	sensitivity	and	specificity	for	
senescent	cell	killing	in	these	mouse	models.	Therefore,	we	used	an	
additional	 distinct,	 potentially	 translatable	 approach	 for	 eliminat‐
ing	senescent	cells,	 that	 is,	 senolytic	drugs,	which	 target	anti‐ap‐
optotic	pathways	in	senescent	cells	and	do	not	depend	on	p16Ink4a 
F I G U R E  2  Eliminating	senescent	cells	enhances	glucose	homeostasis	and	insulin	sensitivity.	(a,	b)	Intraperitoneal	glucose	tolerance	
test	in	DIO	p16‐3MR	(a;	chow	n	=	4,	DIO	n	=	6–7	per	group)	and	DIO	wild‐type	mice	treated	with	D	+	Q	(b,	chow	n	=	4,	DIO	n = 11 per 
group)	following	senescent	cell	clearance.	(c)	Hemoglobin	A1c	in	DIO	p16‐3MR	(chow	n	=	4,	DIO	n	=	15–18	per	group)	and	DIO	wild‐type	
mice	treated	with	D	+	Q	(chow	n	=	6,	DIO	n	=	11–12	per	group).	(d,	e)	ITT	following	ganciclovir	treatment	in	p16‐3MR	mice	(d,	n	=	4	chow,	
n	=	18–19	DIO	groups),	or	D	+	Q	treatment	in	DIO	wild‐type	mice	(e,	chow	n	=	6,	DIO	n	=	11–12	per	group).	(f)	Fold	change	in	AKT	serine‐473	
phosphorylation	after	5‐min	ex	vivo	5	nM	insulin	stimulation	in	freshly	isolated	p16‐3MR	VAT	(n	=	3	per	group).	For	each	mouse,	p‐AKT	
was	normalized	to	total	AKT	and	expressed	as	a	ratio	of	p‐AKT	in	insulin‐exposed	tissue	to	p‐AKT	in	noninsulin‐exposed	tissue.	(g)	Glucose	
infusion	rate	(GIR)	during	hyperinsulinemic–euglycemic	clamp	in	DIO	mice	treated	with	vehicle	or	D	+	Q	(n	=	8	per	group).	(h)	Plasma	insulin	
concentration	at	baseline	and	during	hyperglycemic	clamping	(HGC)	in	DIO	mice	treated	with	D	+	Q	(n	=	8	per	group).	(i)	Glucose	appearance	
rate	(Ra)	during	basal,	hyperglycemic,	and	hyperinsulinemic–euglycemic	clamping	in	DIO	mice	treated	with	D	+	Q	(n	=	8	per	group).	
Means	±	SEM are shown. *p	<	0.05,	**p	<	0.005,	***p	<	0.0005;	one‐way	ANOVA	with	Bonferroni	correction	for	multiple	comparisons.	
#p	<	0.05,	two‐tailed	Student's	t	test	comparing	DIO	vehicle‐treated	group	to	DIO	ganciclovir‐treated,	or	D	+	Q‐treated	group.	Groups	of	
interest	were	compared	at	each	time	point	for	GTTs	and	ITTs
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expression	to	reduce	senescent	cell	burden	(Kirkland	et	al.,	2017;	
Zhu	et	al.,	2015).
Obesity	was	induced	either	by	high‐fat	diet	(diet‐induced	obesity,	
DIO,	with	ad	libitum	chow‐fed	controls)	or	by	genetic	means	in	leptin	
receptor	knockout	(db/db)	mice	(Supporting	Information	Figure	S1).	
Senescent	 cell	 abundance,	 as	 measured	 by	 luciferase	 activity	 in	
p16‐3MR	mice,	 increased	 in	 response	 to	DIO	 compared	 to	 chow‐
fed	 mice	 (Figure	 1a–c	 and	 Supporting	 Information	 Figure	 S2a,b).	
Bioluminescent	imaging	(BLI)	in	ex	vivo	tissues	showed	that	the	most	
prominent	 signal	 was	 present	 in	 visceral	 (specifically	 perigonadal)	
adipose	 tissue	 (VAT;	 Figure	 1c	 and	 Supporting	 Information	 Figure	
S2b).	Although	senescent	cells	are	known	to	accumulate	in	other	or‐
gans	including	the	liver	after	high‐fat	feeding	(Ogrodnik	et	al.,	2017;	
Yoshimoto	et	al.,	2013),	senescent	cell	abundance	detectible	in	ex‐
cised	tissues	by	BLI	was	not	as	pronounced	in	other	adipose	tissue	
depots,	 skeletal	muscle,	 liver,	 and	 pancreas	 (Figure	 1c).	 That	 said,	
limitations	of	BLI,	 including	a	high	threshold	to	visualize	senescent	
cells and limited tissue penetration of the Renilla luciferase	 signal,	
could have contributed to our inability to detect bioluminescence in 
these	other	 tissues.	Therefore,	we	used	additional,	more	 sensitive	
methods	 including	 gene	 expression,	 senescence‐associated	 beta‐
galactosidase	staining,	and	mass	cytometry	to	assess	senescent	cell	
abundance in the studies reported below.
2.2 | Senescent cell clearance improves glucose 
homeostasis and insulin sensitivity
Senescent	 cell	 abundance	 declined	 after	 intermittent	 administra‐
tion	of	ganciclovir	to	p16‐3MR	DIO	mice	(Figure	1a,b,d–f,),	AP20187	
to	DIO	INK‐ATTAC	mice	(Supporting	Information	Figure	S2c,d)	and	
INK‐ATTAC;	 db/db	 mice	 (Supporting	 Information	 Figure	 S2e),	 and	
D	+	Q	 to	 wild‐type	 DIO	 mice	 (Figure	 1g–i).	 CyTOF	 analyses	 con‐
ducted	 after	 a	 single	 course	 of	 AP20187	 or	 D	+	Q	 in	 INK‐ATTAC	
mice showed that adipose tissue senescent cells highly express‐
ing p16Ink4a‐promoter‐induced	FLAG,	CENP‐B,	 or	 p21Cip1 were de‐
creased	 significantly	 (Figure	 1j	 and	 Supporting	 Information	 Figure	
S2f).	 In	 these	 experiments,	 adipose	 progenitor	 cells,	 rather	 than	
endothelial	 cells,	macrophages,	or	T	 cells,	were	 the	main	cell	 type	
targeted	(Supporting	Information	Figure	S2g,h).
Clearing	senescent	cells	improved	glucose	tolerance	(Figure	2a,b	
and	Supporting	Information	Figure	S3a,b)	and	reduced	hemoglobin	
A1c	(HbA1c),	a	marker	of	 long‐term	glucose	control	 (Figure	2c	and	
Supporting	Information	Figure	S3c).	These	effects	were	not	seen	in	
lean,	chow‐fed	control	mice	(Supporting	Information	Figure	S3d–g),	
wild‐type	 (i.e.,	 not	 p16‐3MR)	 DIO	 mice	 treated	 with	 ganciclovir	
(Supporting	Information	Figure	S3h,i),	or	DIO	mice	treated	with	nav‐
itoclax,	which	does	not	target	senescent	adipocyte	progenitors	(Zhu	
et	al.,	2016)	(Supporting	Information	Figure	S3j).	The	time	course	of	
metabolic	improvement	following	initiation	of	D	+	Q	treatment	par‐
alleled	that	of	clearance	of	high	p16Ink4a‐expressing	cells	by	engaging	
death	mechanisms	due	to	transgenes	(Supporting	Information	Figure	
S3k,l).	Eliminating	senescent	cells	did	not	affect	body	weight,	activ‐
ity,	 or	 food	 intake,	 consistent	with	 improved	 glucose	 homeostasis	
being	 due	 principally	 to	 increased	 insulin	 sensitivity	 (Supporting	
Information	Figure	S3m–r).
After	 senescent	 cell	 reduction,	DIO	mice	became	more	 insulin	
sensitive,	as	 indicated	by	insulin	tolerance	testing	(ITT;	Figure	2d,e	
and	 Supporting	 Information	 Figure	 S4a)	 and	 an	 increased	 glu‐
cose	 infusion	 rate	 during	 hyperinsulinemic	 clamping	 (Figure	 2g).	
Furthermore,	 AKT	 Ser473	 phosphorylation	 increased	 in	 response	
to ex vivo insulin stimulation of adipose tissue freshly harvested 
from	animals	that	had	undergone	senescent	cell	clearance	(Figure	2f	
and	 Supporting	 Information	 Figure	 S4b).	 The	 insulin‐positive	 pan‐
creatic islet area remained unchanged after depleting senescent 
cells	 (Supporting	 Information	 Figure	 S4c–e).	 Plasma	 insulin	 con‐
centrations were lower in response to a glucose challenge in both 
p16‐3MR	mice	treated	with	ganciclovir	and	DIO	mice	treated	with	
D	+	Q	 (Supporting	 Information	Figure	S4f,g).	Pancreatic	 insulin	se‐
cretion	was	unchanged	in	D	+	Q‐treated	mice	during	hyperglycemic	
clamping	 experiments	 (Figure	 2h).	 Insulin	 sensitivity	 was	 not	 af‐
fected by genetic interventions that cause elimination of senescent 
cells	in	age‐matched	lean	mice	(Supporting	Information	Figure	S4h)	
or	 obese	WT	mice	 (Supporting	 Information	 Figure	 S4i),	 indicating	
that	off‐target	effects	of	AP20187	or	ganciclovir	are	unlikely	to	have	
contributed substantially to the observed metabolic improvements. 
These	results	indicate	that,	at	least	using	these	methods	for	senes‐
cent	cell	ablation	in	mice	with	DIO‐induced	metabolic	dysfunction,	
metabolic benefits were primarily due to improved peripheral insulin 
sensitivity rather than β‐cell	compensation.	Hepatic	glucose	produc‐
tion	was	also	found	to	be	unchanged	upon	D	+	Q	treatment	in	DIO	
mice	 under	 basal,	 hyperglycemic,	 and	 hyperinsulinemic	 conditions	
(Figure	2i).	Our	 findings	do	not	preclude	 the	possibility	 that	other	
approaches for clearing senescent cells or at different stages during 
development	of	obesity‐induced	metabolic	dysfunction	might	affect	
hepatic glucose production or pancreatic insulin secretion.
2.3 | Adipogenic potential is improved after 
senescent cell reduction
Circulating	 and	 adipose	 tissue	 inflammatory	mediators,	 some	 of	
which	are	components	of	the	SASP	(Coppe	et	al.,	2008;	Tchkonia	
et	al.,	2010),	increase	in	obesity	and	can	impede	adipogenesis	and	
contribute	to	insulin	resistance	(Kahn	&	Flier,	2000;	Xu,	Tchkonia	
et	al.,	2015).	In	p16‐3MR	mice	but	not	WT	mice	treated	with	gan‐
ciclovir,	 plasma	 IFN‐γ	 and	 IL‐1β concentrations were decreased 
(Supporting	Information	Figure	S5a,b).	Cells	expressing	high	con‐
centrations	 of	 TNF‐α isolated from the visceral adipose tissue 
(VAT)	 stromal	 vascular	 fraction	 declined	 upon	 AP20187	 treat‐
ment	 of	 DIO	 INK‐ATTAC	 mice	 (Supporting	 Information	 Figure	
S5c).	 Plasma	 adiponectin,	which	 is	 associated	with	 improved	 in‐
sulin	 sensitivity	 (Kadowaki	 et	 al.,	 2006),	 also	 increased	 after	 se‐
nescent	cell	 reduction	 in	p16‐3MR	mice	 (Supporting	 Information	
Figure	 S5d,e),	 and	 adipose	 tissue	 IFN‐γ expression was reduced 
(Supporting	Information	Figure	S5f).
Activin	 A,	 a	 TGF‐β/GDF‐related	 protein	 that	 is	 a	 component	
of	 the	 senescent	 adipocyte	 progenitor	 SASP	 (Xu,	 Palmer	 et	 al.,	
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F I G U R E  3  Adipogenesis	is	enhanced	by	senescent	cell	reduction.	(a,	b)	Plasma	activin	A	in	p16‐3MR	mice	(a;	chow	n	=	3,	DIO	n	=	9–11)	and	
D	+	Q‐treated	DIO	mice	(b,	chow	n	=	3,	DIO	n	=	11–12).	(c,	d)	Adipogenic	gene	expression	in	cells	isolated	from	subcutaneous	adipose	tissue	
stromal	vascular	fraction	(SVF)	of	p16‐3MR	(c;	n	=	5–7	per	group)	and	D	+	Q‐treated	mice	(d,	n	=	3	per	group).	(e)	Representative	images	of	
lipid	droplet	formation	during	differentiation	of	adipocyte	progenitors	isolated	from	vehicle‐	or	ganciclovir‐treated	p16‐3MR	mice	after	5‐day	
exposure	to	differentiation	medium	(scale	bars	indicate	50	μm).	(f)	VAT	cell	size	in	p16‐3MR	mice	and	D	+	Q‐treated	mice	(n	=	3–7	per	group).	
(g,	h)	Subcutaneous:intra‐abdominal	adipose	ratio	in	DIO	p16‐3MR	mice	(g,	n	=	5–6	per	group)	and	D	+	Q‐treated	mice	(h,	n	=	18–21	per	group).	
Means	±	SEM are shown. *p	<	0.05;	one‐way	ANOVA	with	Bonferroni	correction	or	two‐tailed	Student's	t test when comparing two groups
F I G U R E  4  Senescent	cells	promote	macrophage	infiltration.	(a)	Correlation	of	FLAG+	cells	with	F4/80+/Cd11b+	macrophages	in	the	SVF	
of	DIO	INK‐ATTAC	VAT	as	analyzed	by	CyTOF	(n	=	30).	(b)	Plasma	cytokines	in	ganciclovir‐treated	DIO	p16‐3MR	mice	(n	=	19–22	per	group).	
(c)	F4/80	mRNA	in	VAT	of	ganciclovir‐treated	p16‐3MR	DIO	mice	(chow	n	=	4,	DIO	n	=	17–22	per	group).	(d,	e)	F4/80+	crown‐like	structures	
in	VAT	of	ganciclovir‐treated	p16‐3MR	DIO	mice	(representative	photographs	in	d,	quantified	in	e;	chow	n = 4; DIO n	=	5–8	per	group).	(f)	
THP‐1	cell	migration	into	a	Transwell	containing	either	nonirradiated	or	irradiated	(senescent)	adipocyte	progenitors,	with	no	addition	of	
antibody	(control),	addition	of	nonspecific	antibody	(IgG),	or	addition	of	antibodies	against	MCP‐1,	MIP1‐β,	or	M‐CSF	(n	=	4	per	condition).	(g,	
h)	Representative	image	of	luminescence	signal	in	AP20187‐treated	INK‐ATTAC;db/db mice 24 hr following i.v. injection of 1 × 106 luciferase+ 
monocytes	(g),	normalized	to	vehicle‐treated	mice	and	quantified	in	h	(n	=	6	per	group).	(i)	Quantification	of	luminescence	in	D	+	Q‐treated	
db/db mice 24 hr following i.v. injection of 1 × 106 luciferase+	monocytes	isolated	from	CAG‐luc	mice,	normalized	to	vehicle‐treated	mice	
(n	=	5	per	group).	Means	±	SEM are shown. *p	<	0.05,	**p	<	0.005,	***p	<	0.0005;	one‐way	ANOVA	with	Bonferroni	correction	or	two‐tailed	
Student's	t test when comparing two groups
Chow DIO Vehicle DIO Ganciclovir
(a) (b) (c)
(d)
(f) (g) (h) (i)
(e)
2015),	was	increased	in	DIO	mice	(Figure	3a,b)	and	correlated	with	
highly	p16Ink4a‐expressing	senescent	cell	burden,	as	manifested	by	
p16Ink4a‐promoter‐driven	 luciferase	 expression	 in	 p16‐3MR	 mice	
(Supporting	Information	Figure	S5g).	Activin	A	impedes	expression	
of	 the	 insulin‐sensitizing	 adipogenic	 transcription	 factors	 PPARγ 
and	 C/EBPα,	 thereby	 contributing	 to	 insulin	 resistance	 (Hamm,	
Jack,	Pilch,	&	Farmer,	1999;	Xu,	Palmer	et	al.,	2015;	Zaragosi	et	al.,	
2010).	Senescent	cell	ablation	abrogated	the	DIO‐induced	increase	
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in	activin	A	(Figure	3a,b).	This	was	associated	with	higher	expression	
of adipogenic transcription factors and their targets in adipocyte 
progenitors	from	obese	mice	(Figure	3c,d)	and	enhanced	adipogenic	
differentiation	 in	culture	 (Figure	3e).	These	findings	are	consistent	
with previous data showing that senescent adipocyte progenitors 
develop	a	SASP	that	inhibits	adipogenesis	(Xu,	Palmer	et	al.,	2015).	It	
was	also	previously	found	that	BrdU	incorporation	increases	in	adi‐
pose	tissue	following	AP20187	treatment	in	INK‐ATTAC	mice	(Baker	
et	al.,	2011),	suggesting	that	cleared	senescent	cells	can	be	replaced	
by	 nonsenescent,	 proliferation‐competent	 adipocyte	 progenitors	
that	can	then	differentiate	into	insulin‐responsive	fat	cells.
We	 found	 that	 senescent	 cell	 clearance	 decreases	 adipocyte	
hypertrophy	(Figure	3f	and	Supporting	Information	Figure	S5h)	and	
increases	the	ratio	of	subcutaneous	to	intra‐abdominal	adipose	tis‐
sue	(Figure	3g,h),	reflective	of	better	insulin	sensitivity	(Gustafson,	
Hedjazifar,	Gogg,	Hammarstedt,	&	Smith,	2015).	These	changes	 in	
adipose tissue distribution were mainly due to expansion of subcu‐
taneous	depots	(Supporting	Information	Figure	S5i,j).	Furthermore,	
DIO	INK‐ATTAC	mice	treated	with	AP20187	had	fewer	lipid	droplets	
in	muscle,	measured	by	oil	 red	O	staining	 (Supporting	 Information	
Figure	S5k),	and	less	severe	hepatic	steatosis	(Ogrodnik	et	al.,	2017).	
Collectively,	 these	 findings	 indicate	 that	decreasing	 the	burden	of	
senescent cells may enhance insulin sensitivity in part by improving 
the proliferative and differentiation potential of adipocyte progeni‐
tors,	contributing	to	healthier	adipose	tissue	distribution	and	limiting	
ectopic	lipid	deposition	(Gustafson	et	al.,	2015).
2.4 | Macrophage abundance is correlated with 
senescent cell burden in adipose tissue
Macrophages,	activated	CD4+	lymphocytes,	and	other	immune	cells	
accumulate	in	adipose	tissue	of	obese	individuals	(Olefsky	&	Glass,	
2010;	Tesch,	2007).	Like	senescent	cells,	these	immune	cells	release	
inflammatory	 mediators,	 including	 TNF‐α	 and	 osteopontin,	 which	
can	 contribute	 to	 obesity‐related	 insulin	 resistance	 (Tardelli	 et	 al.,	
2016;	Tesch,	2007).	Events	responsible	for	obesity‐related	immune	
cell	 infiltration	have	remained	 largely	elusive.	 In	VAT	of	DIO	mice,	
macrophage	 abundance	 correlated	with	 highly	 p16Ink4a‐expressing	
senescent	cells	(as	measured	by	p16Ink4a‐promoter‐induced	FLAG)	in	
vivo	(Figure	4a).
Treatment	 with	 ganciclovir	 in	 DIO	 p16‐3MR	 but	 not	 DIO	
wild‐type	 mice	 reduced	 plasma	 concentrations	 of	 the	 macro‐
phage‐attracting	chemokines,	MCP‐1	and	MIP‐1β,	as	well	as	macro‐
phage‐colony‐stimulating	factor	(M‐CSF)	(Figure	4b	and	Supporting	
Information	 Figure	 S6a).	 Expression	 of	 the	 macrophage	 marker,	
F4/80,	significantly	declined	 in	adipose	tissue	after	2–3	months	of	
intermittent	 treatment	 to	 remove	 senescent	 cells	 (Figure	 4c	 and	
Supporting	 Information	 Figure	 S6b),	 and	 fewer	 crown‐like	 struc‐
tures	were	found	 in	perigonadal	adipose	tissue	 (Figure	4d,e).	Also,	
factors	secreted	by	adipose	tissue	activated	T	cells,	 including	IL‐17	
(Supporting	Information	Figure	S6c,d)	and	osteopontin	(Supporting	
Information	Figure	S6e–g;	Tardelli	et	al.,	2016;	Zuniga	et	al.,	2010),	
which	is	also	a	component	of	the	adipose	progenitor	SASP	in	humans	
(Supporting	Information	Figure	S6h),	declined	after	reducing	senes‐
cent cell burden.
Activated	macrophage	contamination	is	a	potentially	significant	
confounder	in	these	studies,	since	macrophages	can	express	p16Ink4a,	
β‐galactosidase,	and	SASP‐like	factors	(Hall	et	al.,	2017).	Unlike	truly	
senescent	 cells,	 macrophages	 can	 revert	 to	 a	 nonactivated	 state,	
potentially	even	into	monocytes	that	replicate.	Therefore,	we	con‐
ducted	 CyTOF	 studies	 and	 specifically	 assayed	 the	 macrophage	
markers,	F4/80	and	Cdllb,	and	verified	that	AP20187	and	D	+	Q	do	
not	 specifically	 and	 immediately	 target	 activated	macrophages,	 as	
this population did not decrease after one round of treatment with 
either	agent	(Supporting	Information	Figure	S2g,h).	 In	addition,	we	
have	 previously	 shown	 that	 D	+	Q	 treatment	 sufficient	 to	 reduce	
senescent preadipocyte abundance does not directly reduce mac‐
rophage abundance in freshly isolated adipose tissue explants from 
obese	human	subjects	(see	Supporting	Information	Figure	S9	in	Xu	
et	al.,	2018).
2.5 | Senescent cell clearance decreases 
macrophage homing to adipose tissue
We	 found	 that	 senescent	 adipocyte	 progenitors	 attract	 mono‐
cytes	in	culture	(Xu,	Tchkonia	et	al.,	2015;	Supporting	Information	
Figure	 S6i)	 and	 that	 this	 effect	 is	 mitigated	 by	 the	 addition	 of	
neutralizing	 antibodies	 against	 the	 SASP	 components	 MCP‐1	
and	MIP‐1β,	 but	 not	M‐CSF	 (Figure	 4f).	 To	 test	 whether	 senes‐
cent cells can directly cause immune cell infiltration and there‐
fore	 whether	 targeting	 senescent	 cells	 reduces	 subsequent	
macrophage	 burden	 in	 adipose	 tissue,	 we	 injected	 monocytes	
that constitutively express luciferase intravenously into lean and 
obese	 (db/db)	 nonluciferase‐expressing	 INK‐ATTAC	 or	 wild‐type	
mice.	We	used	db/db mice in these experiments due to their highly 
inflammatory	adipose	tissue	phenotype.	The	injected	cells	homed	
mainly	 to	 the	VAT	of	obese	mice,	where	obesity‐induced	 senes‐
cent	cells	concentrate,	with	little	to	no	luminescence	detected	in	
F I G U R E  5  Complications	of	diabetes	are	alleviated	by	senescent	cell	clearance.	(a–c)	Parameters	of	diastolic	function	in	p16‐3MR	db/db 
mice	treated	with	ganciclovir	determined	by	echocardiography–Doppler	measurements	(n	=	5–8	per	group):	(a)	Early	diastolic	velocity	from	
medial	mitral	annulus	(e′);	(b)	isovolumic	relaxation	time	(IVRT)	c,	left	ventricular	filling	pressure	(E/e′)	(n	=	5–8	per	group);	(d)	left	ventricular	
ejection	fraction	(EF),	an	indicator	of	systolic	function,	in	p16‐3MR	lean	or	db/db	mice	treated	with	ganciclovir	(n	=	5–8	per	group).	(e)	
Number	of	cells	per	glomerulus	staining	positively	for	Wilms	tumor	protein	in	D	+	Q‐treated	DIO	mice	(WT‐1;	e,	n	=	4	per	group).	(f)	Average	
number	of	p16Ink4a‐positive	cells	per	field	in	the	renal	cortex	of	D	+	Q‐treated	DIO	mice	(n	=	4	per	group).	(g,	h)	Urine	albumin/creatinine	
ratio	(ACR)	in	DIO	p16‐3MR	mice	treated	with	ganciclovir	(g,	chow	n	=	4,	DIO	n	=	9–11	per	group)	or	DIO	wild‐type	mice	treated	with	D	+	Q	
(h,	n	=	6–9	per	group).	Means	±	SEM are shown. *p	<	0.05,	***p	<	0.0005,	****p	<	0.0001;	one‐way	ANOVA	with	Bonferroni	correction	or	
two‐tailed	Student's	t test when comparing two groups
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lean	 mice	 (Supporting	 Information	 Figure	 S6j–l).	 Luciferase‐ex‐
pressing	 monocytes	 injected	 into	 obese	 INK‐ATTAC;db/db mice 
4	days	 after	 AP20187	 treatment,	 or	 into	 wild‐type	 db/db mice 
4	days	after	D	+	Q	treatment,	exhibited	decreased	migration	into	
VAT	 compared	 to	 vehicle‐treated	 mice	 (Supporting	 Information	
Figure	 4g–i).	 AP20187	 had	 no	 evident	 effect	 on	 monocyte	 mi‐
gration in control db/db mice	without	 the	 INK‐ATTAC	 transgene	
(Supporting	Information	Figure	S46m,n).	Thus,	senescent	cells	can	
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cause	macrophage	migration	 into	 adipose	 tissue	 in	 obesity,	 and	
targeting senescent cells prevents and reduces the adipose tissue 
macrophage accumulation that is often associated with obesity.
2.6 | Decreasing senescent cell burden may alleviate 
complications of diabetes
Because	our	interventions	target	senescent	cells	not	only	in	adipose,	
but	also	in	other	tissues,	their	potential	effects	could	exceed	those	
limited	to	alleviating	adipose	tissue	dysfunction.	Senolytics	may	af‐
fect	senescence‐related	comorbidities	associated	with	obesity	(e.g.,	
hepatic	steatosis,	osteoarthritis,	and	neuropsychiatric	dysfunction),	
accelerated	aging‐like	states	associated	with	obesity	(e.g.,	sarcope‐
nia	and	frailty),	and	the	consequences	of	chronological	aging	itself	by	
acting	on	nonadipose	senescent	cells	(Kirkland	et	al.,	2017;	Ogrodnik	
et	al.,	2019;	Palmer	et	al.,	2015).	They	may	also	decrease	the	com‐
plications of diabetes and obesity related to persistent inflammation 
caused	 by	 senescent	 cell	 accumulation,	 including	 cardiovascular	
and	 renal	 dysfunction.	 Indeed,	 senescent	 cell	 clearance	 enhanced	
diastolic	 function	 in	 obese	mice	 (Figure	 5a–c;	 systolic	 function	 as	
measured	by	 left	ventricular	ejection	 fraction	 [EF]	was	unchanged	
[Figure	5d]),	consistent	with	earlier	reports	in	other	models	that	se‐
nescent	 cells	 contribute	 to	 cardiac	dysfunction,	 vascular	 stiffness,	
and	atherosclerosis	 (Childs	et	al.,	2016;	Demaria	et	al.,	2017;	Roos	
et	 al.,	 2016;	 Zhu	 et	 al.,	 2015).	 Additionally,	 renal	 podocytes	 had	
increased	expression	of	Wilms	tumor	protein	 (Wt‐1),	a	measure	of	
podocyte	integrity	and	function	(Figure	5e;	Guo	et	al.,	2002),	after	
D	+	Q	 treatment,	which	also	decreased	p16Ink4a+ cells in renal cor‐
tex	 (Figure	5f).	 Furthermore,	we	 found	decreased	urinary	albumin	
to	creatinine	ratio	(ACR),	an	indicator	of	renal	dysfunction,	after	tar‐
geting senescent cells genetically or with senolytic drugs in obese 
mice	(Figure	5g,h).	Thus,	senolytics	may	alleviate	senescence‐associ‐
ated	complications	of	metabolic	dysfunction,	beyond	the	impact	of	
glucose‐lowering	and	insulin	sensitization	that	senolytics	share	with	
certain currently available diabetes treatments.
3  | DISCUSSION
Our study indicates in several different models that senescent cell 
clearance may be an effective strategy for alleviating important ele‐
ments	of	obesity‐related	metabolic	dysfunction.	Senolytic	treatment	
recapitulated	metabolic	 improvements	 seen	after	 transgene‐medi‐
ated	clearance	of	senescent	cells.	Senescent	cells	may	not	only	drive	
insulin	resistance	directly	through	their	SASP,	but	also	promote	adi‐
pose tissue immune cell infiltration and impair progenitor cell func‐
tion.	More	investigation	is	needed	into	the	relative	contributions	of	
each of these mechanisms to insulin resistance and complications 
of diabetes.
The	transgenic	models	used	in	these	studies	are	dependent	on	
targeting	high	p16Ink4a	expression.	Not	every	senescent	cell	has	high	
p16Ink4a,	and	there	are	cell	 types	that	have	a	transient	elevation	 in	
p16Ink4a	that	are	not	truly	senescent,	such	as	activated	macrophages	
(Hall	 et	 al.,	 2017).	 These	 points	 suggest	 that	 interpreting	 studies	
based	on	 targeting	cells	with	high	expression	of	p16Ink4a alone re‐
quires	 caution,	 so	we	 also	 used	 senolytics	 to	 test	 our	 hypothesis.	
Effects	 of	 D	+	Q	 do	 not	 depend	 on	 high	 p16Ink4a	 expression,	 but	
rather on transiently disabling the survival pathways protecting se‐
nescent cells from apoptosis.
It is possible that other senolytic agents may have distinct or 
complementary	effects	to	those	of	D	+	Q	in	diabetes,	since	senolyt‐
ics vary considerably in the spectra of senescent cell types that are 
targeted.	Thus,	targeting	different	types	of	senescent	cells	and	de‐
termining the effects of various combinations of different senolyt‐
ics,	as	well	as	behavioral	interventions	(e.g.,	exercise	[Schafer	et	al.,	
2016]	or	dietary	interventions),	will	be	important	next	steps	in	har‐
nessing	the	benefits	of	these	drugs.	This	might	open	opportunities	
to	create	individualized	treatments	by	targeting	particular	senescent	
cell types in patients with different constellations of symptoms and 
complications	of	metabolic	disease.	Another	key	step	will	be	to	test	
effects of different senolytics on metabolic dysfunction and its com‐
plications	across	a	broad	range	of	animal	models	of	diabetes,	includ‐
ing	type	1	diabetes,	and	studies	in	primates	in	preparation	for	clinical	
trials.
Importantly,	initial	human	trials	of	senolytics	for	other	conditions	
are	 underway.	 Indeed,	 the	 first	 clinical	 trial	 of	 senolytics	 was	 re‐
cently reported. Improvements in physical function of patients with 
idiopathic	pulmonary	fibrosis	were	found	 in	a	pilot	study	of	D	+	Q	
(Justice	et	al.,	2019).	Similar	pilot	clinical	trials	and	ultimately	larger,	
longer	duration,	 randomized	double‐blind	placebo‐controlled	 trials	
are needed to test the potential therapeutic benefits of senolytics in 
diabetic	patients,	including	alleviation	of	complications	of	metabolic	
disease	such	as	cardiovascular,	renal,	and	neurological	dysfunction.	
Critically,	since	D	+	Q	was	given	 intermittently	and	the	elimination	
half‐life	of	each	drug	is	<12	hr	(Christopher	et	al.,	2008;	Graefe	et	al.,	
2001),	the	observed	effects	are	consistent	with	reduced	senescent	
cell	 burden,	 rather	 than	 effects	 on	 senescence‐independent	 sig‐
naling	pathways,	 receptors,	or	enzymes	that	 require	 the	sustained	
presence	 of	 drugs.	 Thus,	 intermittent	 administration	 of	 senolytics	
may	delay	or	alleviate	diabetes,	complications	of	both	obesity	and	di‐
abetes,	and	other	comorbidities	associated	with	senescence‐related	
chronic	diseases,	a	possibility	that,	if	further	confirmed	in	pre‐clini‐
cal	studies,	merits	examination	in	clinical	trials.
4  | E XPERIMENTAL PROCEDURES
4.1 | Animals
Mice	 heterozygous	 for	 either	 the	 p16‐3MR	 or	 INK‐ATTAC	
transgenes	on	a	C57BL/6	background	were	used	in	these	experi‐
ments	 (Demaria	et	al.,	2017;	Xu,	Palmer	et	al.,	2015).	 J.L.K.,	T.T.,	
J.	 van	Deursen,	and	D.	Baker	 (all	 currently	at	Mayo)	devised	 the	
strategy	and	characterized	 INK‐ATTAC	mice	 (Baker	et	 al.,	 2011).	
The	ATTAC	 construct	was	 devised	 by	 P.	 Scherer,	who	 sent	 it	 to	
J.L.K.	 p16‐3MR	 mice	 were	 generously	 provided	 by	 Dr.	 Judith	
Campisi.	 Leptin	 receptor	 knockout	 heterozygotic	 (Leprdb/−)	 mice	
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were	 purchased	 from	 Jackson	 Laboratory	 (Bar	 Harbor,	ME)	 and	
crossed	to	either	p16‐3MR	mice	or	 INK‐ATTAC	mice	to	generate	
mice	homozygous	for	the	 leptin	receptor	mutation	(db/db).	CAG‐
luc	 transgenic	 C57BL/6	 mice	 were	 obtained	 from	 the	 Jackson	
Laboratory	 (Stock	 No:	 025854).	 The	 CAG‐luc	 mouse	 expresses	
firefly	 luciferase	 driven	 by	 the	 constitutively	 active	 CAG	 pro‐
moter	in	most	tissues.	Ages	of	mice	used	in	each	experiment	are	
reflected	 in	 Supporting	 Information	 Figure	 S1.	Male	 and	 female	
mice were used for db/db experiments.	Male	mice	were	used	for	
DIO	experiments	due	to	their	increased	susceptibility	to	high‐fat	
diet‐induced	 metabolic	 dysfunction.	 For	 diet‐induced	 obesity	
(DIO)	 experiments,	mice	were	maintained	 on	 a	 60%	 (by	 calorie)	
fat	diet	(D12492,	irradiated;	Research	Diets,	New	Brunswick,	NJ).	
Lean	 control	 mice	 were	 fed	 a	 normal	 chow	 diet	 (LabDiet	 5053,	
13.2%	fat	by	calorie,	St.	Louis,	MO).	Mice	were	maintained	under	
a	12‐hr	light	and	12‐hr	dark	cycle	at	24°C	with	free	access	to	food	
and	water	 in	 a	 pathogen‐free	 facility.	All	 studies	were	 approved	
by	the	Mayo	Clinic	Institutional	Animal	Care	and	Use	Committee.
4.2 | Cell strains
THP‐1 cells	were	purchased	from	ATCC	(Manassas,	VA).
Human adipocyte progenitors,	also	termed	adipose‐derived	stem	
cells	or	preadipocytes	(Tchkonia	et	al.,	2013),	were	isolated	from	ab‐
dominal subcutaneous adipose tissue biopsies from nine healthy sub‐
jects	undergoing	surgery	to	donate	a	kidney	(age	37	±	6	years,	male,	
BMI	26	±	2).	These	cells	were	used	for	osteopontin	measurements	in	
senescent	cells	and	for	THP‐1	migration	studies.	These	studies	were	
approved	by	the	Mayo	Clinic	Institutional	Review	Board.
4.3 | Drug treatments
Ganciclovir	(Genentech,	San	Francisco,	CA;	25	mg/kg),	dissolved	in	
water	and	phosphate‐buffered	saline	 [PBS])	or	PBS	alone,	was	ad‐
ministered	i.p.	for	five	consecutive	days,	with	10–14	days	between	
the last dose of one treatment round and the first day of the next 
treatment	round.	AP20187	(MedchemExpress,	Monmouth	Junction,	
NJ;	10mg/kg,	dissolved	 in	ethanol	 for	 stock	 solution,	 then	diluted	
in	PEG‐400	and	2%	Tween	for	dosing	solution)	or	PEG‐400/Tween	
2%	 in	 water	 (vehicle)	 was	 administered	 by	 i.p.	 injection	 for	 three	
consecutive	days,	with	12	days	between	treatments.	Dasatinib	(LC	
Laboratories,	Woburn,	MA;	5	mg/kg)	and	quercetin	(Sigma	Aldrich,	
St.	 Louis,	 MO;	 50	mg/kg)	 or	 vehicle	 (60%	 Phosal,	 10%	 ethanol,	
and	 30%	 PEG‐400)	 were	 administered	 for	 five	 consecutive	 days	
monthly via	oral	gavage	in	cohort	1,	or	for	three	consecutive	days,	
with 14 days between the last dose of one treatment round and the 
first	 day	 of	 the	 next	 treatment	 round	 in	 cohort	 2.	 For	CyTOF	ex‐
periments,	a	single	course	of	AP20187	(3	days)	or	D	+	Q	(5	days)	was	
given	3	days	prior	to	sacrifice.	Navitoclax	(Active	Biochem,	Kowloon,	
Hong	 Kong;	 50	mg/kg)	 or	 vehicle	 (60%	 Phosal,	 10%	 ethanol,	 and	
30%	PEG‐400)	was	administered	via oral gavage for five consecutive 
days	monthly.	Body	composition	was	measured	by	EchoMRI	(Echo	
Medical	Systems,	Houston,	TX).
4.4 | Metabolic testing
For	DIO	and	lean	mice,	glucose	tolerance	and	insulin	tolerance	test‐
ing	(ipGTT,	ITT,	respectively)	were	performed	by	injecting	1.2	g/kg	
glucose	or	0.8	mU/kg	 insulin	 (i.p.)	 in	 the	early	afternoon	 following	
a	6‐hr	or	4‐hr	 fast,	 respectively.	Glucose‐stimulated	 insulin	 secre‐
tion	(GSIS)	in	DIO	and	lean	mice	was	measured	after	oral	gavage	of	
1.5	g/kg	 glucose	 following	 a	 4‐hr	 fast.	 Intraperitoneal	 injection	of	
glucose	was	used	for	GTT	due	to	increased	excursion	of	blood	glu‐
cose,	allowing	for	better	differentiation	between	treatment	groups.	
Oral administration of glucose was used for insulin secretion meas‐
urements	in	Figure	2h	to	ensure	the	most	physiologic	 induction	of	
insulin	secretion	(including	the	contribution	of	incretins),	as	well	as	to	
test the overall validity of our results by testing improvements with 
senescent	cell	clearance	in	multiple	assays.	For	db/db	mice,	glucose	
tolerance	 testing	was	performed	by	 injecting	1.0	g/kg	 glucose	 i.p.	
following	an	overnight	 fast.	Tail	 vein	blood	glucose	was	measured	
at time 0 and at indicated time points using a handheld glucometer 
(Bayer	Breeze	2	[Bayer,	Whippany,	NJ],	or	for	db/db mice,	AlphaTrak	
[Zoetis,	 Parsippany,	 NJ]).	 Aside	 from	 clear	 weight	 differences	 be‐
tween lean and DIO or db/db	 mice,	 the	 experimenter	 conducting	
GTT,	ITT,	and	GSIS	testing	was	unaware	of	the	treatment	group	as‐
signment	of	each	mouse	during	testing.	HbA1c	was	measured	using	
a	commercial	test	(A1cNow+,	Bayer,	Whippany,	NJ).	Plasma	insulin,	
adiponectin,	activin	A,	and	osteopontin	were	measured	using	com‐
mercial	ELISA	kits	(insulin	and	adiponectin:	ALPCO,	Salem	NH;	os‐
teopontin	and	activin	A:	R&D	Systems,	Minneapolis	MN).
4.5 | Hyperglycemic clamp experiments
Mice	were	fasted	from	9	hr	before	the	experiment	until	the	end	of	
the	experiment.	The	study	was	divided	into	three	periods,	(a)	a	basal	
period	 in	which	only	glucose	 tracer	was	 infused,	 (b)	 a	hyperglyce‐
mic	period	(HGC)	in	which,	next	to	the	glucose	tracer,	glucose	was	
infused at a variable rate to maintain blood glucose levels at about 
20	mM,	and	(c)	a	hyperinsulinemic–euglycemic	period	(HIEC)	during	
which,	in	addition	next	to	the	glucose	tracer,	insulin	was	infused	at	a	
constant rate and glucose was infused at a variable rate to maintain 
blood	glucose	levels	at	about	6	mM.	During	all	three	periods,	blood	
glucose	 levels	 and	 glucose	 infusion	 rates	 were	 monitored,	 from	
which	kinetic	parameters	were	calculated.
4.6 | Adipocyte progenitor isolation
The	stromal	vascular	fraction	of	perigonadal	adipose	tissue	was	iso‐
lated	by	collagenase	digestion	as	previously	described	(Tchkonia	et	
al.,	2005).
4.7 | Mass cytometry (CyTOF)
We	designed	 a	 panel	 of	 antibodies	 based	on	 surface	markers,	 tran‐
scription	factors,	and	cytokines	(see	Supporting	Information	Table	S1).	
Each	antibody	was	tagged	with	a	rare	metal	isotope	and	its	function	
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verified	 by	mass	 cytometry	 according	 to	 the	 factory	manual	 (Multi	
Metal	 labeling	 kits;	 Fluidigm	 South	 San	 Francisco,	 CA).	 A	 CyTOF‐2	
mass	cytometer	(Fluidigm)	was	used	for	data	acquisition.	Acquired	data	
were	normalized	based	on	normalization	beads	(Ce140,	Eu151,	Eu153,	
Ho165,	and	Lu175).	Stromal	vascular	cells	were	isolated	from	epididy‐
mal	white	adipose	tissue.	Collected	cells	were	incubated	with	metal‐
conjugated	antibodies	and	for	testing	intracellular	proteins,	including	
transcription	 factors	 and	 cytokines.	 Fixation	 and	 permeabilization	
were	conducted	according	to	the	manufacturer's	instructions	(Foxp3/	
Transcription	Factor	Staining	Buffer	Set,	eBioscience,	San	Diego,	CA).	
CyTOF	data	were	analyzed	by	Cytobank	(Santa	Clara,	CA).	Total	pro‐
genitors	 were	 defined	 as	 CD45−,	 CD31−,	 and	 Sca1+.	 Macrophages	
were	defined	as	F4/80+	and	CD11b+.	Endothelial	 cells	were	defined	
as	CD31+	and	CD146+.	T	lymphocytes	were	defined	as	CD4+	or	CD8+. 
Upon testing of antibodies to Renilla	 luciferase,	we	found	that	back‐
ground	signals	were	too	high	in	WT	mice	to	be	specific	enough	to	use	
in	these	experiments.	Therefore,	we	pursued	CyTOF	experiments	 in	
the	INK‐ATTAC	model	rather	than	the	p16‐3MR	model.
4.8 | Plasma cytokine profiling
Plasma	cytokines	were	quantified	using	multiplex	ELISA	on	a	Bio‐
Plex	200	analyzer	by	Eve	Technologies	(Calgary,	Alberta,	Canada).
4.9 | Quantitative real‐time PCR
Quantitative	real‐time	PCR	was	performed	as	described	previously	
(Xu,	Palmer	et	al.,	2015).	Primer	catalog	numbers	are	in	Supporting	
Information	Table	S2.
4.10 | Western blotting
Western	blotting	was	performed	as	described	previously	(Xu,	Palmer	
et	al.,	2015).
4.11 | Adipose tissue analyses
SA‐β‐gal	 activity	was	 assayed	 as	 reported	previously	 (Xu,	Palmer	 et	
al.,	2015).	Briefly,	a	small	piece	of	adipose	tissue	was	collected	in	PBS,	
lightly	fixed	with	glutaraldehyde	and	formaldehyde	for	15	min,	washed	
3X	in	PBS,	and	placed	in	SA‐β‐gal	activity	solution	containing	X‐gal	at	
pH	6.0	at	37°C	for	14–16	hr.	Tissues	were	rinsed	in	PBS,	nuclei	were	
stained	with	DAPI,	and	adipose	tissue	was	compressed	between	two	
glass	slides	for	light	microscopy.	SA‐β‐gal+ cells as a percent of all nuclei 
were	quantified	in	at	least	10	images	taken	at	random	per	tissue	using	
NIS‐Elements	 software	 (Nikon	 Instruments,	 Melville,	 NY).	 Neither	
the	person	who	captured	images	for	quantification	nor	the	observer	
counting	SA‐β‐gal+ cells in the captured images was aware of the iden‐
tity	of	the	samples.	Photographs	of	SA‐β‐gal+	tissue	chunks	were	taken	
after	5–8	hr	of	 incubation	at	37°C.	Cell	 size	was	quantified	using	at	
least	10	images	taken	at	random	from	adipose	tissue	chunks	by	light	
microscopy by measuring diameters of all completely visible adipo‐
cytes	per	field	using	Nikon	NIS‐Elements	software.
4.12 | Ex vivo insulin response assay
Adipose	tissue	was	cut	into	small	pieces	(<100	mg)	and	washed	with	PBS	
3	times.	The	minced	tissue	was	treated	with	5	nM	insulin	or	vehicle	(PBS)	
for	5	min	at	37°C.	p‐AKT	(#4060)	and	total‐AKT	(#4691)	antibodies	for	
Western	analyses	were	purchased	from	Cell	Signaling	(Danvers,	MA).
4.13 | Albumin–creatinine ratio
Albumin	 was	 measured	 by	 ELISA	 (GenWay,	 San	 Diego,	 CA),	 and	
creatinine	 was	 measured	 by	 colorimetric	 assay	 (MaxDiscovery;	
Bio	 Scientific,	Austin,	 TX)	 in	 urine	 collected	 from	nonfasted	mice.	
Albumin–creatinine	 ratio	 (ACR)	was	 calculated	by	determining	mi‐
crogram of albumin per mg of creatinine.
4.14 | Conditioned medium experiments
Stromal	vascular	collagenase	digests	were	plated,	replated	within	18	hr,	
and	serially	sub‐cultured	for	4	population	doublings	using	differential	
plating and culture media designed to select against macrophage or 
endothelial	 cell	 contamination.	 Cells	were	 exposed	 to	 10	Gy	 radia‐
tion	or	were	sham‐irradiated.	After	25	days,	irradiated	cells	acquired	
senescent	morphology,	 developed	 SA‐β‐gal	 activity,	 and	 expressed	
p16INK4A	and	SASP	components.	Cells	were	washed,	and	serum‐free	
conditioned	medium	(CM)	was	collected	and	passed	through	a	0.2‐µm	
filter.	CM	was	concentrated	using	3K	concentrators	(Amicon	Ultra‐15	
Centrifugal	Filter	Units,	Millipore,	Darmstadt,	Germany)	and	analyzed	
by	 LC/MSMS	 (Q	 Exactive™	 Hybrid	 Quadrupole‐Orbitrap™	 Mass	
Spectrometer,	ThermoFisher,	Waltham,	MA)	for	osteopontin.
4.15 | Adipocyte progenitor differentiation
To	 induce	differentiation	of	mouse	cells,	80%	confluent	adipocyte	
progenitors were exposed to differentiation medium containing 
DMEM/F‐12,	 10%	 FBS,	 1μg/ml	 insulin,	 	 250	nM	 dexamethasone,	
0.5mM	 IBMX,	 	 and	 2.5μM	 rosiglitazone	 for	 48	 hours	 at	 20%	O2. 
Medium	was	then	replaced	with	DMEM/12	containing	only	10%	FBS	
and	insulin,	and	kept	in	culture	for	an	additional	5–8	days.
4.16 | Comprehensive laboratory animal 
monitoring system
Metabolic	 rate	 and	 food	 intake	 were	 measured	 using	 a	
Comprehensive	Laboratory	Animal	Monitoring	System	(CLAMS)	as	
previously	described	(Xu,	Tchkonia	et	al.,	2015).
4.17 | THP‐1 macrophage migration
Migration	 assays	 were	 performed	 using	 Transwell	 polycarbon‐
ate	membrane	 inserts	with	 a	5‐μm pore diameter purchased from 
Corning	 (Corning,	 NY).	 THP‐1	 cells	 were	 stained	with	 CellTracker	
CM‐DiI	 dye	 (Thermo	 Fisher	 Scientific,	 Waltham,	 MA)	 according	
to	 the	manufacturer's	 directions	 and	 then	 plated	 into	 the	 inserts.	
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Nonsenescent	control	or	senescent	human	primary	adipocyte	pro‐
genitors	were	seeded	into	the	bottom	chambers	of	the	plates.	After	
24	hr,	 DiI‐labeled	 THP‐1	 cells	 that	 had	 migrated	 into	 the	 bottom	
chamber were imaged.
For	 neutralizing	 antibody	 experiments,	 THP‐1	 cells	 (105)	 were	
plated	 into	Transwell	 inserts	and	allowed	to	migrate	 into	the	bottom	
chamber	for	6	hr	at	37°C.	After	6	hr,	the	number	of	cells	that	had	mi‐
grated	into	the	lower	chamber	was	quantified	using	the	CyQUANT	Cell	
Proliferation	Assay	Kit	(Life	Technologies)	according	to	the	manufactur‐
er's	instructions.	All	neutralizing	antibodies	were	purchased	from	R&D.	
The	concentrations	for	the	antibodies	in	the	CM	are	Goat	IGG	(1	mg/
ml),	M‐CSF	(1	mg/ml),	MCP1	(0.2	mg/ml),	and	MIP‐1b	(0.2	mg/ml).
4.18 | Monocyte infiltration
Monocytes	 were	 isolated	 from	 femur	 and	 tibial	 bone	 marrow	 of	
CAG‐luc	transgenic	C57BL/6	mice	using	a	commercial	kit	(Monocyte	
Isolation	kit,	MACS	Miltenyi	Biotec,	San	Diego,	CA).	1	×	106 mono‐
cytes	in	PBS	were	injected	i.v.	via the tail vein in db/db or lean mice. 
Luminescent signal was examined 24 hr after monocyte injection.
4.19 | Luminescence imaging
Both	Renilla and firefly luminescence imaging were performed using 
a	Xenogen	IVIS	200	system	(Caliper	Life	Sciences,	Hopkinton,	MA).	
To	detect	p16‐3MR	Renilla	 luciferase‐expressing	cells,	200	µl	 coe‐
lenterazine	 h	 (Rediject,	 PerkinElmer)	 was	 injected	 i.p.	 into	 each	
mouse	10	min	before	imaging	was	initiated.	For	firefly	luminescence,	
3	mg	d‐luciferin	 (Gold	Biotechnology,	St.	Louis,	MO)	 in	200	µl	PBS	
was injected i.p. into each mouse 5 min before imaging was initiated. 
The	exposure	for	luminescence	images	was	5	min.
4.20 | Echocardiography
High‐resolution	 ultrasound	 imaging	 was	 used	 to	 evaluate	 cardiac	
function	as	previously	described	(Roos	et	al.,	2016).
4.21 | Anti‐Wilms tumor protein 
immunohistochemistry
Formalin‐fixed	 paraffin‐embedded	 mouse	 kidney	 tissue	 sections	
were	subjected	to	steam	heat‐mediated	antigen	retrieval	for	30	min	in	
10	mM	sodium	citrate	buffer,	pH	6.0.	Samples	were	then	incubated	at	
room	temperature	for	1	hr	with	primary	antibody	(Anti‐Wilms	Tumor	
Protein;	Abcam	#ab89901)	 diluted	1/100,	 followed	by	 a	 30‐min	 in‐
cubation	in	a	Ready‐to‐Use	HRP‐Labelled	secondary	antibody	(Dako	
K4003).	 Color	 was	 developed	 using	 Vector	 NovaRED	 Peroxidase	
Substrate	Kit	(SK‐4800)	followed	by	hematoxylin	counterstaining.
4.22 | Quantification and statistical analyses
When	comparing	two	groups,	unpaired	two‐tailed	Student's	t tests 
were used. p	<	0.05	was	 considered	 significant.	One‐way	ANOVA	
with	Bonferroni	correction	was	used	to	estimate	statistical	signifi‐
cance	when	more	than	two	groups	were	being	compared.	All	values	
are	expressed	as	mean	±	SEM.	Sample	sizes	were	chosen	based	on	
the	means	and	variation	of	preliminary	data	to	achieve	at	least	80%	
power	and	allowing	for	5%	type	I	error.
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